Processa CEO buys 2,129 shares in open market

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,129 shares of Common Stock at $2.57 per share on May 29, 2026.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,129 shares of Common Stock at $2.57 per share on May 29, 2026. Following this transaction, his direct holdings increased to 9,970 Common Stock shares.

The filing also lists indirect ownership positions of 800 Common Stock shares held through the Ng Cha Family Trust and 3,488 Common Stock shares held through an account labeled George Ng IRRA FOB George Ng, reflecting additional indirect exposure to Processa shares.

Insider Trade Summary

Net Buyer: 2,129 shares

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 2,129 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,129	$2.57	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,970 shares (Direct); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng); Common Stock — 800 shares (Indirect, Ng Cha Family Trust)

Key Figures

Shares purchased: 2,129 shares Purchase price: $2.57 per share Direct holdings after transaction: 9,970 shares +2 more

5 metrics

Shares purchased 2,129 shares Open-market purchase on May 29, 2026

Purchase price $2.57 per share Price for 2,129 Common Stock shares

Direct holdings after transaction 9,970 shares Common Stock directly owned after purchase

Indirect holdings via Ng Cha Family Trust 800 shares Common Stock held indirectly

Indirect holdings via IRRA account 3,488 shares Common Stock held indirectly in George Ng IRRA FOB George Ng

Key Terms

open-market purchase, indirect ownership, Common Stock, Form 4, +1 more

5 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""direct_or_indirect": "I", "ownership_type": "indirect""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

net-buy financial

""netBuySellDirection": "net-buy""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Processa Pharmaceuticals (PCSA) report for George K. Ng?

Processa’s CEO George K. Ng reported buying 2,129 shares of Common Stock in an open-market transaction. The shares were purchased on May 29, 2026 at a price of $2.57 per share, increasing his directly held stake in the company.

How many Processa (PCSA) shares does George K. Ng hold directly after this Form 4?

After the reported transaction, George K. Ng directly holds 9,970 shares of Processa Common Stock. This figure comes from the Form 4 line showing total shares following the open-market purchase, and represents only his direct ownership position, not including indirect holdings.

At what price did Processa’s CEO purchase PCSA shares in the latest filing?

George K. Ng purchased Processa Common Stock at $2.57 per share. The Form 4 describes this as an open-market or private transaction purchase, covering 2,129 shares executed on May 29, 2026, and explicitly labels the transaction as a buy in the filing data.

What indirect Processa (PCSA) holdings are associated with George K. Ng?

The Form 4 lists 800 Processa Common Stock shares held indirectly through the Ng Cha Family Trust and 3,488 shares held indirectly through an account labeled George Ng IRRA FOB George Ng. Both positions are classified as indirect ownership interests linked to the reporting person.

Does the Processa (PCSA) Form 4 filing show any insider sales by George K. Ng?

The Form 4 data show a net-buy pattern for George K. Ng, with one open-market purchase of 2,129 shares and no reported sales. Additional entries reflect indirect holdings with unknown transaction codes, but no lines are labeled as sale transactions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		P		2,129	A	$2.57	9,970	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)